The clock is ticking for BayWa. By April 30, the agricultural and energy group expects to pocket €107 million from the sale of its Dutch subsidiary Cefetra Group — a payment that could be the difference between a credible restructuring and a full-blown crisis. But even if the cash lands on time, the company remains in a perilous position, with a €2.7 billion funding gap, a regulatory probe, and a looming decision from its core lenders that could sink the entire rescue plan.
The Cefetra Windfall: More Than a Payment
The sale of Cefetra to a European investor consortium was operationally closed in the first quarter of 2026. The final tranche — €45 million in residual purchase price and roughly €62 million from the repayment of shareholder loans — is now due. If it arrives punctually, it will strengthen BayWa’s negotiating hand with its core banks, DZ Bank and HVB, and signal that the restructuring blueprint is on track.
The deconsolidation of Cefetra has already slashed BayWa’s bank debt by more than €600 million. Combined with other divestments — including its stakes in RWA and EDL — the group has chipped away at liabilities by around €1.3 billion since the restructuring began. The ultimate target remains daunting: a €4 billion reduction in debt by 2028.
A Bank Decision That Could Break Everything
The Cefetra payment is a subplot in a much larger drama. The core of BayWa’s survival hinges on a standstill agreement with DZ Bank and HVB. If the lenders agree to extend it, BayWa buys time until autumn 2026. If they refuse, the restructuring collapses immediately.
That original rescue plan has already been blown off course. A sale of a 51% stake in the energy division was supposed to generate around €1.7 billion by 2028. But deteriorating conditions for project developers in the US — a key market — rendered that plan obsolete. The fallout: a debt haircut, 1,300 job cuts, and fire sales of assets.
Goldman Sachs has been brought in to market New Zealand fruit trading subsidiary T&G Global, with analysts estimating a sale price of roughly €300 million. But minority shareholder Joy Wing Mau of Hong Kong, which holds nearly 20%, is seen as a potential complication.
Supervision Tightens as Legal Storms Gather
Parallel to the financial squeeze, BayWa is overhauling its governance. Supervisory board members Michael Höllerer and Monika Hohlmeier stepped down from their capital mandates on March 31, with Monique Surges to follow at the end of May. The search is on for successors with expertise in restructuring and digital transformation.
Should investors sell immediately? Or is it worth buying BayWa?
The board has also dramatically tightened internal controls. Transactions above €50 million now require supervisory board approval — down from a threshold of €200 million, a stark signal of the heightened oversight.
Meanwhile, the regulatory and legal pressure is escalating. In November 2024, Germany’s financial watchdog BaFin ordered a special audit of the 2023 consolidated financial statements. The issue: the accounts allegedly omitted details on credit terms and refinancing risks tied to a €500 million bond and short-term debt instruments worth €632 million. PricewaterhouseCoopers has lost its auditing mandate, and BayWa’s management is exploring damages claims against the former auditors. Law firm TILP is preparing lawsuits for shareholders who invested between early 2022 and January 2026.
For the cooperative banks, the pain is already real. Bavaria’s Volks- und Raiffeisenbanken have written down €132 million on a promissory note loan. GVB President Stefan Müller has publicly warned of a potential total write-off.
The Long Wait for Clarity
The audited 2025 consolidated financial statements won’t be available until the fourth quarter of 2026. BayWa’s management has withdrawn its 2026 forecast entirely. The adjusted EBITDA target for 2027 stands at around €140 million — sharply reduced from earlier ambitions. By 2028, the group aims to shrink from a €24 billion conglomerate to a focused company with roughly €10 billion in revenue.
The stock currently trades at around €12.75, down from a 52-week high of €21.50 — a decline of more than 33%. Since the start of the year, it has lost about 14% of its value.
The next major milestone comes on May 6, when BayWa publishes its first-quarter 2026 report. Investors will be looking for evidence that cost-cutting — including the closure of 26 locations and the elimination of 1,300 jobs — is already supporting the bottom line. If the Cefetra cash arrives by April 30, it will give the group a much-needed boost in refinancing talks with its banks.
But two events will ultimately determine BayWa’s fate: the bank agreement and the audited annual report. Both are expected no earlier than the fourth quarter of 2026. Until then, investors are navigating without a reliable data compass.
Ad
BayWa Stock: Buy or Sell?! New BayWa Analysis from April 24 delivers the answer:
The latest BayWa figures speak for themselves: Urgent action needed for BayWa investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from April 24.
BayWa: Buy or sell? Read more here...
